▲ Peaking
Business
EyePoint Stock Craters 69% After Drug Trial Failure. It May Be an Overreaction.
EyePoint shares experience a sharp decline following the release of pivotal data regarding the company's primary drug candidate.
4 trends tracked about this subject — the full history, oldest to newest below.
EyePoint shares experience a sharp decline following the release of pivotal data regarding the company's primary drug candidate.
3 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
3 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Takeda's historic narcolepsy approval ignites a wave of new pharmaceutical development in the sleep drug market.